Clinical trial

Prevention of Post-photocoagulation Macular Edema by Intravitreal Bevacizumab.

Name

APEC-035

Description

to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision

Trial arms

Trial start

2008-12-01

Estimated PCD

2008-12-01

Trial end

2008-12-01

Status

Withdrawn

Phase

Early phase I

Treatment

Bevacizumab

Intravitreal administration

Arms:

Group 1

Panretinal Photocoagulation

Arms:

Group 2

Primary endpoint

Best Corrected Visual Acuity

Eligibility criteria

Inclusion Criteria: * Patients with Proliferative retinopathy or severe non-proliferative retinopathy * BCVA of 20/63 or better (56 ETDRS letters * No history of Macular Edema * Central Retinal Thickness of 250mics or more Exclusion Criteria: * Previous treatment. * Other ophthalmic diseases. history of Nephropathy, heart diseases and pregnancy * Media opacities

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'primaryPurpose': 'TREATMENT'}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}

Updated at

2024-05-30

1 organization

1 drug

1 indication

Organization

Asociación para Evitar la Ceguera en México

Drug

Atezolizumab

Indication

Macular Edema